Zoë Johnson Email & Phone Number

Switzerland

Geneva, GE, CH

Geneva, GE, CH

Milton, England, GB

MTM is run by entrepreneurs for entrepreneurs. We specialise in co-creating and scaling companies within our global ecosystem by blending experienced drug discovery with agile operations to foster breakthroughs and deliver transformative medicines.

London, GB

Geneva, Switzerland, CH

Adiposs has developed ImageBAT, a first-in-class medical imaging product for brown adipose tissue. Fast and simple imaging of activated brown fat holds promise in diagnosing and stratifying patients in a range of diseases such as cancer (predicting response to immunotherapy), obesity, cardiovascular disease and chronic kidney disease.

• Executing the rapid transition of AFVT-2101, a novel innate immune cell engager, to IND-readiness
• Develop preclinical and translational strategy for lead program
• Develop pipeline through evaluation of in-licensing opportunities
• Lead fund raising activities
• Lead publication and IP strategy and filings
• Founder member of the leadership team, built the Affivant team out from scratch

Geneve, CH

• Two small molecule drugs progressed to clinical stage in 3 years
• Membership of the executive leadership team, operationalize and shape the R&D and IP strategy
• Manage budget, assign resource and prioritize activities to maximize the value of the pipeline
• Participate in fund raising activities
• Lead publication strategy and represent iOnctura at international conferences
• Organize and lead the scientific advisory board; report directly to CEO/Board of Directors

Geneve, CH

Plan-les-Ouates, Genève, CH

• Support to phase II/III mAb development leading to successful BLA filing of Gamifant (emapalumab)
• Responsible for overseeing the delivery of robust, product-specific bioanalytical endpoints (drug concentration, immunogenicity, biomarkers, pharmacodynamic markers) for nonclinical and clinical studies, in line with.
• Set the bioanalytical and translational strategies for monitoring of monoclonal and bispecific antibody activity in healthy subjects and patients
• Work in close collaboration with the clinical team and Chief Medical Officer to ensure appropriate clinical trial support within tight timelines
• Write and review study reports, assay validation reports and regulatory submissions
• Manage discussions and setting up of contracts with external providers for outsourced studies (CROs). Monitored the transfer, development and validation of out-sourced work

Plan-les-Ouates, Genève, CH

• Successful pre-clinical development of NI-1701 (a CD47xCD19 bispecific, now TG-1801) from candidate selection through to IND-readiness
• Managed the Translational Pharmacology and Experimental Biology groups (8 scientists)
• Devised, guided and interpreted the collection of preclinical data into suitable packages to support clinical filings and partnering activities
• Responsible for the in vivo, in vitro, and ex vivo pharmacokinetic /pharmacodynamic models and biomarker identification
• Delivered reports summarizing results of preclinical PK/PD and in vivo experimental analysis
• Applied scientific findings from studies to support the design of preclinical safety assessment and clinical studies

Darmstadt, Hessen, DE

• Led the preclinical PK/PD and biomarker department in the Immunology Therapy Area, with a team of 10 scientists
• Identified new therapeutic programs for rheumatology, gastroenterology, bone diseases, dermatology through innovative thinking, search & evaluation and repurposing of existing projects / products
• Built and led high performing cross functional project teams to meet industry standard milestone progression for two small molecule and one biologic drug program
• Joint project leader on a collaboration with Ablynx

Brussels, BE

• Conceptualized and developed in vivo assays, in order to study the pharmacology or mechanism of action of small molecules or biologicals.
• Delivered in vivo pharmacology data to support all TA-Inflammation projects from hit discovery to early development.
• Developed novel antibody technology platforms
• Represented Therapeutic Area in cross-functional project teams
• Supervised and trained junior scientists and undergraduate students
• Initiated and managed collaborations with UK and European academic labs

Plan-les-Ouates, Genève, CH

Short-term post doctoral position in a start-up biotechnology company. Principal role involved setting up and characterising murine proof of concept assays and disease models. Major contribution to the initiation and implementation of an antibody program for inflammatory disease.

A PhD student in the immunology and protein biochemistry departments. The work arising from this project directly influenced a pre-clinical research program and led to the identification of a clinical candidate biologic.

Graduate research scientist in the respiratory disease group. Responsible for setting up and running small animal models of lung inflammation to screen small molecule drugs.

Basel, Basel-Stadt, CH

Industrial sandwich placement undertaken during 3rd year of undergraduate degree. Experience gained in respiratory pharmacology research division where I assisted in developing and characterising an in vivo model of lung inflammation to screen small molecule receptor antagonists.

Phd, Pharmacology

Bsc (Hons), Biological Sciences